Enanta Pharma (ENTA) Misses Q4 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017
November 20, 2017 4:01 PM ESTWebcast and Conference Call today at 4:30 p.m. ET
Cash and marketable securities totaled $293.7 million at September 30, 2017 Total revenue for the quarter was $75.9 million Milestone payments totaling $65.0 million received following AbbVies U.S. approval of MAVYRET (glecaprevir/pibrentasvir) and EU approval of MAVIRET (glecaprevir/pibrentasvir) Positive Phase 1 results for EDP-305 support further clinical evaluation in PBC and NASH patients Fast Track designation granted to EDP-305 by the U.S. FDA for the treatment of patients with primary... More